RE:RE:RE:RE:RE:RE:RE:RE:RE:Cytodyn downIt is one of the nuttiest things I have ever seen. And I have seen a lot of nutty things over my 45 years of investing. It has been obvious forever that CYDY likely had nothing medically and were a financial basket case . Yet they were able to get a huge valuation from retail investors. TH has done so much better than CYDY but you would never know that from the stock performance.
Wino115 wrote: Don't get me wrong, it's pure junk company and doubt they'll ever be there for HIV. I just thought it's an interesting lesson that in the end, you have to have the science and explain it accurately. Their fatal flaw is now exposed unless they restaff the place. By the way, that seekingalpha guy wrote that before the full report we all read. I'm in no way supporting those guys, but his numbers are actually wrong but it shows you how horrible and self-contradictory their PR was. It really is laughable. They literally changed around and mistakenly renamed the various subgroups so it looks like they cherry-picked, but those are the trial data subgroups agreed to in the protocal in the report and not modified at all, just stupidly renamed in their bizarre PR. That efficacy number I posted is exactly from the report and for something like 90% of the participants. It's a real number but you'd never know it from them! Hilarious how badly they botched it.
jfm1330 wrote: And by the time they will have real results, enough for approval, chances are that the pandemic in the US will be at much lower level. It is alrady down by a lot, and with expanded vaccination, it should go down even more. That being said, variants are still a worry, also, will enough people accept to get the vaccine. If the US administration is able to get to 80% or more vaccinated, real return to normal should happen somewere in the coming months. So where will be the market for Cytodyn in covid? Where will be the market in MDR HIV with Trogarzo and Fostemsavir already on the market? A tiny part of a very niche market for a druf that works only on half of MDR HIV patients, those with only the R5 strain, not the X4. All that to say that even with some approval in covid and HIV, it does not justify a high stock price. They have close to 600 millions shares outstanding plus warrants plus options. This is just crazy.